Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Forsythoside E: PKM2 Mechanism to Assays
2026-09-14
Forsythoside E is a phenolic glycoside and pyruvate kinase M2 (PKM2) inhibitor candidate with a distinctive tetramer-stabilizing mechanism. This assay-centered guide connects chemical identity, macrophage metabolism, STAT3 signaling, and sepsis-induced liver injury research while clarifying evidence limits.
v-Agatoxin-IVA and N-Type Calcium Channel Blockade
2026-09-14
Sidach and Mintz showed that v-Agatoxin-IVA is not exclusively a high-affinity P-type calcium-channel blocker: at higher exposure, it also inhibits a fraction of neuronal N-type currents through a voltage-dependent, gating-modifier mechanism. The study refines pharmacological classification of P- and Q-type channels and provides important controls for interpreting toxin-based calcium-current experiments.
Afatinib in Gastric Cancer Assembloid Research
2026-09-13
Afatinib, also known as BIBW 2992, enables irreversible ErbB-family perturbation in patient-derived gastric cancer organoids and assembloids. Its most informative use is comparative: testing how matched stromal populations alter EGFR, HER2, and HER4 inhibitor sensitivity, signaling, and resistance.
EZ Cap™ Firefly Luciferase mRNA Workflow
2026-09-12
Build a quantitative reporter workflow that separates mRNA delivery, translation, cellular energy, and assay timing. EZ Cap™ Firefly Luciferase mRNA (m1Ψ) combines Cap1, modified nucleotides, and a poly(A) tail for a practical benchmark in transfection, protein-expression, and imaging studies.
Heparin sodium for Nanovesicle Uptake Studies
2026-09-11
Heparin sodium links validated coagulation control with a practical competition assay for testing heparan sulfate proteoglycan-dependent nanovesicle uptake. This workflow helps distinguish Sertoli-cell targeting effects from downstream biology while providing orthogonal anti-factor Xa and aPTT quality checks.
Platanoside, Ferroptosis, and Acute Lung Injury
2026-09-11
The reference study identifies an autophagy-dependent Keap1 degradation mechanism through which platanoside activates the Nrf2/GPX4 antioxidant axis and limits ferroptosis-associated acute lung injury. Its findings connect molecular pathway regulation with oxidative, mitochondrial, inflammatory, and histological outcomes, while also highlighting the limits of translating an LPS-induced mouse model into broader ALI biology.
(5Z)-7-Oxozeaenol: Mapping TAK1 Causality
2026-09-10
Discover how (5Z)-7-Oxozeaenol functions as a selective TAK1 inhibitor for separating inflammatory signaling from AMPK–SQSTM1 metabolic adaptation. This article translates recent lysosomal stress findings into a causal, assay-centered workflow for interpreting NF-κB, JNK/p38 MAPK, COX-2, AMPK, and NRF2 readouts.
USP42, JNK/p38, and Breast Cancer Apoptosis
2026-09-10
A 2025 Scientific Reports study identifies USP42 as a pro-tumorigenic factor in breast cancer and connects its depletion to activation of JNK/p38 signaling and apoptosis. The work combines expression analysis, loss-of-function experiments, pathway inhibition, and xenograft testing, providing a mechanistic framework while leaving direct USP42 substrates and clinical applicability for further study.
NamiRNA–LNP Therapy in Pancreatic Cancer
2026-09-09
Yu et al. show that miR-200c suppresses pancreatic cancer through two distinct regulatory routes: enhancer-dependent activation of PTPN6 transcription and post-transcriptional repression of CDH17. LNP-based delivery extended this mechanism into an in vivo therapeutic framework, while also illustrating how proliferation and migration should be measured as related but separable phenotypes.
Cardamomin and Oxidative Protection in Ischemic Stroke
2026-09-09
The reference study identifies cardamomin from Amomum villosum Lour. as a preclinical protector against hydrogen peroxide-induced oxidative injury and permanent cerebral ischemia. Its main contribution is a connected mechanism involving MEK/ERK-dependent NRF2 activation, suppression of oxeiptosis, and limitation of AIFM1-associated parthanatos, supported by complementary cellular and rat experiments.
SB743921 Workflows for Mitotic Arrest Studies
2026-09-08
Build more informative KSP-inhibition assays by separating mitotic growth arrest from irreversible cell death. This workflow uses SB743921 for mechanism-focused profiling, concentration optimization, and translational comparison across cancer cell lines and tumor xenograft models.
Birinapant (TL32711): From IAP Biology to Translation
2026-09-08
Birinapant (TL32711) offers a mechanistically focused way to test how IAP-dependent survival signaling shapes apoptosis and treatment response. By connecting its SMAC mimetic activity with evidence linking MDM1, p53, and apoptosis to chemoradiotherapy sensitivity, this article presents a biomarker-led framework for translational cancer research.
Leucovorin Calcium in Cancer Assays
2026-09-07
Leucovorin Calcium enables controlled methotrexate-rescue experiments in organoids, assembloids, and cell proliferation assays. This workflow uses calcium folinate to distinguish epithelial folate dependence from stromal modulation while improving interpretation of antifolate drug resistance research.
Protoporphyrin IX in Ferroptosis Workflows
2026-09-07
Protoporphyrin IX enables paired dark–light experiments that separate photodynamic stress from iron- and lipid-dependent cell death. This practical guide connects heme formation, photodynamic cancer diagnosis, and the METTL16–SENP3–LTF ferroptosis axis while emphasizing formulation, controls, and interpretation limits.
Abiraterone Acetate in 3D Prostate Models
2026-09-05
Use Abiraterone acetate as a controlled CYP17 inhibitor challenge in patient-derived prostate spheroids, while separating target biology from solubility and exposure effects. This workflow combines three-dimensional viability, androgen receptor activity inhibition, biomarker profiling, and practical troubleshooting for more defensible prostate cancer research.
8792 records 8/587 page Previous Next First page 上5页 678910 下5页 Last page